Xalkori bags FDA green light for rare paediatric non-Hodgkin lymphoma
Therapy approved for the treatment of paediatric patients with anaplastic large cell lymphoma
Read More
Tag: non-Hodgkin lymphoma
Servier acquires Pixuvri from CTI BioPharma
The treatment was approved for use in the European Union in June this year.
Read More
Rituximab found to extend progression-free survival in indolent lymphoma
New trial results have been published showing that a combination of Celgene’s Revlimid and Roche’s rituximab significantly extended progression-free survival in patients with relapsed or refractory indolent lymphoma, compared to rituximab with placebo.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
